eMedicine Specialties > Physical Medicine and Rehabilitation > Disorders of the Motor Unit

Hereditary Spastic Paraplegia: Differential Diagnoses & Workup

Author: Nam-Jong Paik, MD, PhD, Chief, Associate Professor of Rehabilitation Medicine, Rehabilitation Medicine, Seoul National University Bundang Hospital
Coauthor(s): Jae-Young Lim, MD, Assistant Professor, Department of Rehabilitation Medicine, Division of Musculoskeletal Rehabilitation, Bundang Hospital, Seoul National University College of Medicine
Contributor Information and Disclosures

Updated: Jul 29, 2008

Differential Diagnoses

Dopamine-Responsive Dystonia
Syphilis
HIV Infection and AIDS
Syringomyelia
Hydrocephalus
Krabbe Disease
Metachromatic Leukodystrophy

Other Problems to Be Considered

Hereditary motor-sensory neuropathy type 5
Spondylosis
Atlantoaxial canal stenosis
Arteriovenous malformation compressing spinal cord
Arnold-Chiari syndrome
Tethered cord
Neoplasm
Granuloma
Spinocerebellar ataxias
Adrenomyeloneuropathy
Deficiency of vitamins B-12 and E
Abetalipoproteinemia
Mitochondrial disorders
Human T-cell lymphocytotrophic virus infection
Toxins
Stiff-limb syndrome

Related eMedicine topic:
Vitamin B-12 Associated Neurological Diseases

Workup

Laboratory Studies

  • Presently, genetic loci (designated SPG1 through SPG23, in order of their discovery) have been identified for 10 autosomal dominant, 8 autosomal recessive, and 3 X-linked types of HSP. Ten HSP genes have been discovered.4,5,6,7
  • With regard to autosomal dominant pure HSP, SPG4, SPG3A, and SPG6 account for 50-60% of families.
    • SPG4 HSP is the single most common dominantly inherited HSP, representing approximately 40% of such cases. Hazan and colleagues discovered that mutations in a novel gene designated SPG4 (protein, spastin) are the cause of this disorder.8 Genetic testing for SPG4/spastin mutations is available commercially, can provide laboratory confirmation of the diagnosis, and can be applied to prenatal testing. Insights into SPG4 phenotype and spastin function can yield useful information relating to hypotheses for axonal degeneration in SPG4 HSP, such as direct cytoskeletal instability, abnormal mitochondrial distribution, and other consequences of abnormal axonal transport.5,9,10,11
    • A second autosomal dominant HSP (SPG3A) shows a linkage to band 14q11-q21. This is also a pure HSP. Symptoms usually begin in early childhood and are often nonprogressive. Genetic testing for SPG3A is commercially available.
    • A third autosomal dominant HSP, SPG6, shows a linkage to band 15q11.1. Symptoms begin in late teenage years. This kindred contains a number of affected members who have developed more severe disability than is typical in HSP families with other linkages.
  • SPG5, SPG7, and FALDH are involved in autosomal recessive HSPs.
    • A family with pure HSP has demonstrated a linkage to band 8q12-q13 (SPG5 HSP).
    • Autosomal recessive SPG7 HSP has been linked to mutations in the gene encoding for paraplegin.5,12 Mutations in the gene result in impaired oxidative phosphorylation.
    • Another autosomal recessive form of HSP, Sjögren-Larsson syndrome, is a disorder of the fatty aldehyde dehydrogenase gene (FALDH) and is associated with seizures.
  • With regard to X-linked HSP, the border between pure and complicated HSP syndromes is blurred.
    • SPG1 HSP is linked to mutations in the gene for the L1 cell adhesion molecule; these mutations are associated with spasticity, ataxia, and mental retardation.
    • SPG2 HSP is linked to a missense mutation in the gene for proteolipid protein, which is located on band Xq21. Mutations in this gene are also related to complicated X-linked HSP and to Pelizaeus-Merzbacher syndrome.
  • Preliminary genotype-phenotype correlations are as follows:
    • With the identification of HSP loci on chromosome X and 2p, 8q, 14q, 15q, and 16q, a comparison of phenotypes is possible in families for whom the disorder is linked to one of these loci, as well as in HSP families for whom these loci are excluded.13
    • Thus far, genetically diverse types of autosomal dominant HSP (those linked to 2p, 14q, and 15q) appear to be clinically and electrophysiologically similar. This observation suggests that the different abnormal gene products may interact in a common biochemical cascade that results in similar patterns of neuronal degeneration.
    • The disorder may be more severe in the 15q-linked kindred than in kindreds linked with 14q.
    • In a study of the kindred with disease linked to 14q, only 1 patient needed a wheelchair.14 In contrast, 9 of the patients affected in a kindred HSP linked to 15q required a wheelchair (for some patients, the need began in their 40s).
    • Kindreds with autosomal dominant HSP linked to 2p have exhibited (1) the prototypical adolescent- or adult-onset, progressive form and (2) the less common childhood-onset, relatively nonprogressive form. The significant variations in patients' ages at symptom onset and the degree of progression in these kindreds indicate that the complete phenotype is influenced by different mutations in the same gene or by the effects of modifying genes.

Related eMedicine topics:
Pelizaeus-Merzbacher Disease
Sjogren-Larsson Syndrome

Imaging Studies

  • Magnetic resonance imaging (MRI) scans may demonstrate atrophy of the spinal cords and occasionally of the cerebral cortex.2

Other Tests

  • Electrophysiologic studies are useful for assessing peripheral nerve, muscle, dorsal column, and corticospinal tract involvement in patients with HSP.15 Because it is uncommon to obtain permission to perform an autopsy, these studies are particularly useful for characterizing the extent of involvement. Although the results of these studies are variable, a number of generalizations can be made. Most studies have found nerve conduction test results to be normal (in contrast to results in Friedrich ataxia and some other spinocerebellar ataxias). One study, however, showed that subclinical sensory impairment was common in patients with HSP, with involvement of peripheral nerves and/or spinal pathways.
    • Lower extremity somatosensory evoked potentials show a conduction delay in dorsal column fibers.
    • Cortical evoked potentials used to measure neurotransmission in corticospinal tracts show greatly reduced conduction velocity in the corticospinal tract and greatly reduced amplitude of the evoked potential.
    • Often, no cortical evoked potentials are elicited in muscles innervated by lumbar spinal segments, but cortical evoked potentials of the arms are normal or show only mildly reduced conduction velocity. These findings indicate that decreased numbers of corticospinal tract axons are reaching the lumbar spinal cord and that the remaining axons have reduced conduction velocity.
    • Schady and colleagues emphasized the variable results of cortical evoked potentials.16 In their patients, central motor conduction velocity in the upper extremities was normal except for all 5 affected members of one HSP kindred for whom responses were considerably delayed. Shady concluded that measurement of central motor conduction velocity may be a useful way of identifying clinical subgroups of HSP.17
  • The cerebrospinal fluid is usually normal, although increased protein is noted in some patients.

Histologic Findings

  • The major neuropathologic feature of pure, autosomal dominant HSP is axonal degeneration that is maximal in the terminal portions of the longest descending and ascending tracts (ie, crossed and uncrossed corticospinal tracts to the legs and fasciculus gracilis, respectively). Autopsy studies have demonstrated the loss of axons in the ventral and lateral corticospinal tracts.
  • Spinocerebellar fibers are involved to a lesser extent. Neuronal cell bodies of degenerating fibers are preserved, and no evidence of primary demyelination is noted. Loss of anterior horn cells is observed in some cases. Dorsal root ganglia, posterior roots, and peripheral nerves are normal.
  • The regional pattern of axonal degeneration in pure HSP is different from that seen in system degeneration diseases, such as amyotrophic lateral sclerosis (ALS). System degeneration in ALS includes cortical (ie, pyramidal) neurons, corticospinal tracts, anterior horn cells innervated by corticospinal tracts, and skeletal muscle. Parkinson disease, characterized by loss of dopaminergic neurons in the substantia nigra pars compacta and secondary changes in brain regions that receive this dopaminergic innervation, may exemplify another system degeneration.
  • Axonal degeneration in pure, autosomal dominant HSP involves different classes of neurons (eg, corticospinal tract fibers from pyramidal neurons in the motor cortex; fasciculus gracilis; cuneatus to a lesser extent, from dorsal root ganglia neurons). One obvious feature shared by these degenerating axons is their length. These fibers are the longest in the CNS. Degeneration was maximal in the distal axons of these fibers.

More on Hereditary Spastic Paraplegia

Overview: Hereditary Spastic Paraplegia
Differential Diagnoses & Workup: Hereditary Spastic Paraplegia
Treatment & Medication: Hereditary Spastic Paraplegia
Follow-up: Hereditary Spastic Paraplegia
Multimedia: Hereditary Spastic Paraplegia
References

References

  1. Sawhney IM, Bansal SK, Upadhyay PK, et al. Evoked potentials in hereditary spastic paraplegia. Ital J Neurol Sci. Sep 1993;14(6):425-8. [Medline].

  2. Reid E. Pure hereditary spastic paraplegia. J Med Genet. Jun 1997;34(6):499-503. [Medline][Full Text].

  3. Appleton RE, Farrell K, Dunn HG. 'Pure' and 'complicated' forms of hereditary spastic paraplegia presenting in childhood. Dev Med Child Neurol. Apr 1991;33(4):304-12. [Medline].

  4. Fink JK. Advances in the hereditary spastic paraplegias. Exp Neurol. Nov 2003;184 Suppl 1:S106-10. [Medline].

  5. Tallaksen CM, Durr A, Brice A. Recent advances in hereditary spastic paraplegia. Curr Opin Neurol. Aug 2001;14(4):457-63. [Medline].

  6. Züchner S. The genetics of hereditary spastic paraplegia and implications for drug therapy. Expert Opin Pharmacother. Jul 2007;8(10):1433-9. [Medline].

  7. Paisan-Ruiz C, Dogu O, Yilmaz A, et al. SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia. Neurology. Apr 15 2008;70(16 Pt 2):1384-9. [Medline].

  8. Hazan J, Fonknechten N, Mavel D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. Nov 1999;23(3):296-303. [Medline].

  9. Depienne C, Stevanin G, Brice A, et al. Hereditary spastic paraplegias: an update. Curr Opin Neurol. Dec 2007;20(6):674-80. [Medline].

  10. Fink JK, Rainier S. Hereditary spastic paraplegia: spastin phenotype and function. Arch Neurol. Jun 2004;61(6):830-3. [Medline].

  11. Orlacchio A, Patrono C, Gaudiello F, et al. Silver syndrome variant of hereditary spastic paraplegia: A locus to 4p and allelism with SPG4. Neurology. May 20 2008;70(21):1959-66. [Medline].

  12. Tzoulis C, Denora PS, Santorelli FM, et al. Hereditary spastic paraplegia caused by the novel mutation 1047insC in the SPG7 gene. J Neurol. Jun 23 2008;[Medline].

  13. Fink JK, Heiman-Patterson T, Bird T, et al. Hereditary spastic paraplegia: advances in genetic research. Hereditary Spastic Paraplegia Working Group. Neurology. Jun 1996;46(6):1507-14. [Medline].

  14. Hazan J, Lamy C, Melki J, et al. Autosomal dominant familial spastic paraplegia is genetically heterogeneous and one locus maps to chromosome 14q. Nat Genet. Oct 1993;5(2):163-7. [Medline].

  15. Schady W, Smith CM. Sensory neuropathy in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry. Jun 1994;57(6):693-8. [Medline][Full Text].

  16. Schady W, Dick JP, Sheard A, et al. Central motor conduction studies in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry. Sep 1991;54(9):775-9. [Medline][Full Text].

  17. Claus D, Waddy HM, Harding AE, et al. Hereditary motor and sensory neuropathies and hereditary spastic paraplegia: a magnetic stimulation study. Ann Neurol. Jul 1990;28(1):43-9. [Medline].

Further Reading

Keywords

hereditary spastic paraplegia, HSP, hereditary spastic paraparesis, familial spastic paraparesis, Strumpell-Lorrain syndrome, Strumpell-Lorrain disease, Strümpell-Lorrain syndrome, Strümpell-Lorrain disease, pure hereditary spastic paraplegia, uncomplicated hereditary spastic paraplegia, complicated hereditary spastic paraplegia

Contributor Information and Disclosures

Author

Nam-Jong Paik, MD, PhD, Chief, Associate Professor of Rehabilitation Medicine, Rehabilitation Medicine, Seoul National University Bundang Hospital
Nam-Jong Paik, MD, PhD is a member of the following medical societies: American Association of Neuromuscular and Electrodiagnostic Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Jae-Young Lim, MD, Assistant Professor, Department of Rehabilitation Medicine, Division of Musculoskeletal Rehabilitation, Bundang Hospital, Seoul National University College of Medicine
Jae-Young Lim, MD is a member of the following medical societies: American Association of Neuromuscular and Electrodiagnostic Medicine
Disclosure: Nothing to disclose.

Medical Editor

Teresa L Massagli, MD, Residency Director, Professor, Department of Rehabilitation Medicine and Pediatrics, University of Washington School of Medicine
Teresa L Massagli, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Physical Medicine and Rehabilitation, and Association of Academic Physiatrists
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kat Kolaski, MD, Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine
Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center
Disclosure: Nothing to disclose.

Chief Editor

Denise I Campagnolo, MD, MS, Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St. Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consort
Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers
Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.